13 results about "Normal flora" patented technology

The invention provides an antibacterial peptide RB3 and application thereof. The amino acid sequence of the antibacterial peptide RB3 is as shown in SEQ ID NO: 1. The antibacterial peptide RB3 has remarkable antibacterial activity on five endometritis pathogenic bacteria, namely, E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa and E. faecium, can be used for inhibiting the growth and proliferation of the endometritis pathogenic bacteria and maintaining a normal flora structure and an immune microenvironment of endometrium, and can be used for preparing the antibacterial peptide RB3. The antibacterial peptide RB3 has the advantages that the antibacterial peptide RB3 has obvious antibacterial activity on the five endometritis pathogenic bacteria, namely, E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, P. mirabilis, P. aeruginosa and E. faecium; according to the present invention, the antibacterial peptide RB3 can be directly obtained through solid-phase synthesis, such that the effective prevention and treatment of endometritis can be achieved, the important significance on the prevention and the clinical treatment of endometritis can be provided, and the antibacterial peptide RB3 can be directly obtained through solid-phase synthesis so as to easily achieve the large-scale preparation and the clinical large-scale application of the antibacterial peptide RB3.

This application provides a *Lactobacillus curvatureii* bacteriocin, its preparation method, and its application, relating to the field of biotechnology. The *Lactobacillus curvatureii* bacteriocin provided in this application is obtained through gene recombination expression and is a natural antibacterial ingredient with a broader antibacterial spectrum, low irritation, and long-lasting effect. Applying this *Lactobacillus curvatureii* bacteriocin to feminine hygiene products not only enhances the product's antibacterial effect but also helps repair and maintain the balance of the microecology, preventing disruption of normal flora, effectively maintaining the acidic environment of the intimate area, inhibiting the growth of pathogenic bacteria, and reducing the risk of infection. The feminine hygiene product of this application combines gentleness, high efficacy, and multifunctionality, while also focusing on microecological balance and mucosal repair to meet the higher needs of women's intimate care.

The invention discloses a preparation method of a monoclonal antibody for detecting trichophyton rubrum and application of the monoclonal antibody in fungal skin disease detection, and belongs to the field of biological medicine. The monoclonal antibody provided by the invention only has specific reaction with trichophyton rubrum, and has no cross reaction with common fungi such as trichophyton mentagrophytes, epidermophyton flocculent, candida albicans, malassezia and the like and normal flora of a human body, so that a false positive result is effectively avoided. Based on the double-antibody sandwich principle, the detection sensitivity can reach 200 pg / mL level, trace trichophyton rubrum in a clinical sample can be detected, and the positive rate is obviously higher than that of direct microscopic examination. The whole detection process can be completed within 15-20 min and is far faster than fungus culture for several weeks, a rapid diagnosis basis can be provided for doctors, and early treatment is facilitated. The kit provided by the invention has standardized operation steps, does not need complex instruments and special training, and is suitable for popularization and use in clinical laboratories of hospitals at all levels, outpatient clinics of dermatology and even basic medical institutions.

The present application belongs to the technical field of microbial prevention and treatment, and particularly relates to a mycobacterium phage and application thereof. Specifically, the present application successfully screens a mycobacterium phage MP1 capable of precisely targeting and killing mycobacterium marinum, which can precisely target and kill specific mycobacterium marinum without causing adverse effects on normal flora. This feature enables the phage therapy to avoid the adverse reactions and flora imbalance problems caused by antibiotic treatment when treating drug-resistant mycobacterium marinum. Meanwhile, the above-mentioned mycobacterium phage MP1 is obtained from nature and is easy to be industrialized, and a drug or environmental disinfectant prepared from the above-mentioned phage not only can reduce the cost, but also has the advantages of green environmental protection and the like, and therefore has good practical application value.

The invention belongs to the technical field of microbial control, and particularly relates to a mycobacterium marinum bacteriophage and application thereof. Specifically, the mycobacteriophage MP1 capable of accurately targeting and killing mycobacterium marinum is successfully screened, and the mycobacteriophage MP1 can accurately target and kill specific mycobacterium marinum without generating adverse effects on normal flora. Due to the characteristic, when the bacteriophage therapy is used for treating the drug-resistant mycobacterium marinum, the problems of adverse reaction and dysbacteriosis caused by antibiotic treatment are avoided. Meanwhile, the mycobacteriophage MP1 is obtained from the nature and is easy to industrially produce, and the medicine or the environmental disinfectant prepared from the mycobacteriophage can reduce the cost and has the advantages of being green, environmentally friendly and the like, so that the mycobacteriophage MP1 has good practical application value.

The invention discloses a targeted antibacterial tooth paste based on an enzyme specific response mechanism as well as a preparation method and application thereof. The targeted antibacterial tooth paste consists of the following components in percentage by weight: 30-80% of a film-forming agent, 2-40% of a humectant, 0.2-2% of a thickening agent, 0.2-5% of a flavoring agent, 0.1-5.0% of an active medicine and 0.1-20.0% of an enzyme sensitive unit, according to the invention, a wrapping technology is innovatively introduced, effective components are wrapped in the sensitive unit with enzyme specific response, the sensitive unit has an intelligent response and active targeting mechanism, after the specific pathogenic bacterium characteristic enzyme is triggered, the drug is accurately released at the infected part, the frequency of drug use is lower, the side effect is smaller, the normal flora in the oral cavity is protected, and the safety is higher. According to the dental patch, the defect that a traditional dental patch releases drugs indiscriminately is overcome, intelligent response to a dental plaque biofilm is achieved, and the dental patch has wide application prospects in the aspect of precise prevention and treatment of periodontitis, caries and other oral diseases.

The invention provides an antibacterial peptide as well as a screening method and application thereof. On the first aspect, the invention provides the antibacterial peptide, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO. 1. The antibacterial peptide has high specificity on staphylococcus aureus in a certain concentration range, has no inhibition effect on other common skin symbiotic bacteria such as staphylococcus epidermidis, staphylococcus vorus and propionibacterium acnes, can avoid damage to normal flora balance of a human body, reduces the risk of secondary infection, and has a good application prospect. The problem of flora imbalance caused by broad-spectrum killing of the existing antibacterial peptide is solved. In addition, the minimum inhibitory concentration on staphylococcus aureus is low, the obvious bacteriostatic effect can be achieved under the condition of lower dosage, and the medicine dosage and potential side effects are reduced. In addition, the compound is derived from human skin symbiotic microorganisms and has good biocompatibility with the human body, in-vitro cytotoxicity experiments prove that the effective antibacterial concentration of the compound has no obvious toxicity on human skin keratinocytes, and the safety of the compound is superior to that of chemically synthesized antibacterial molecules.

The invention provides a bacillus cereus bacteriophage and application thereof, and belongs to the technical field of bacteriophages. The preservation number of the bacillus cereus phage provided by the invention is CCTCC (China Center For Type Culture Collection) NO: M 20251545. The bacteriophage provided by the invention can specifically split bacillus cereus and remarkably reduce the colonization amount of the bacillus cereus in the respiratory tract, so that lung inflammatory response caused by swine influenza virus infection is effectively relieved, lung tissue injury is reduced, infection symptoms are relieved, and remarkable interference on normal florae of a host is avoided. According to the technical scheme, a new direction is provided for development and utilization of the bacteriophage in the antiviral field, and compared with traditional antibiotics, the bacteriophage serving as a natural antibacterial agent has the advantages of precise targeting, self-replication, low toxicity and the like and has a wide application prospect in the aspect of prevention and treatment of influenza virus infection.

The invention provides an antibacterial peptide RB12 and application of the antibacterial peptide RB12 in preparation of a medicine for preventing and / or treating uterine cavity diseases. The amino acid sequence of the antibacterial peptide RB12 is as shown in SEQ ID NO: 1. The antibacterial peptide RB12 provided by the invention has antibacterial activity on four endometritis pathogenic bacteria, namely, escherichia coli, klebsiella, proteus mirabilis and staphylococcus aureus, and particularly, the antibacterial rate on the escherichia coli is close to 80%, and the antibacterial peptide RB12 can inhibit growth and proliferation of the endometritis pathogenic bacteria; according to the present invention, the antibacterial peptide RB12 can be directly obtained through solid-phase synthesis, such that the normal flora structure and the immune microenvironment of the endometrium can be easily maintained so as to achieve the effective prevention and treatment of the endometritis, the important significance is provided for the prevention and the clinical treatment of the endometritis, and the antibacterial peptide RB12 can be directly obtained through solid-phase synthesis so as to easily achieve the large-scale preparation and the clinical large-scale application of the antibacterial peptide RB12.

The invention belongs to the technical field of oral care solutions, and particularly provides an oral care solution for treating and preventing ventilator-associated pneumonia and a preparation method of the oral care solution. Honeysuckle, Chinese lobelia, coptis chinensis, liquorice, fortune eupatorium herb, mint, cinnamon, clove, catechu and aloe are adopted as raw materials and are subjected to proper weight proportioning. Under the combined action of the medicinal components, the traditional Chinese medicine composition has the effects of killing and inhibiting bacteria, clearing away heat and toxic materials and astringing wound. The oral care solution disclosed by the invention adopts pure Chinese herbal medicine components, is high in safety after long-term use, relatively weak in irritation to oral mucosa and very small in influence on a production environment of normal flora, and does not cause disorder of oral strains; the oral care solution provided by the invention is suitable for oral care of critical patients, and can effectively treat and / or prevent the occurrence of ventilator-associated pneumonia of the critical patients.

This invention belongs to the field of biomedical engineering and ophthalmic anti-infective therapy technology, specifically relating to a bacteriophage XP2 for treating Bacillus cereus endophthalmitis and its applications. Bacteriophage XP2 was deposited on November 18, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 47001. The bacteriophage provided by this invention exhibits high specificity in killing host bacteria, acting only against the host bacteria without disrupting normal flora or inducing widespread drug resistance. Simultaneously, the bacteriophage itself is non-toxic to normal retinal function and demonstrates excellent preservation of retinal function, even superior to vancomycin treatment, with a shorter onset time than vancomycin, approximately 30 minutes. This invention confirms the effectiveness of bacteriophage XP2 in directly reducing the bacterial load in Bacillus cereus-induced endophthalmitis and indirectly controlling inflammatory damage. By rapidly killing bacteria, XP2 minimizes neutrophil-induced inflammatory responses while protecting retinal structure and function.

The invention discloses an oral medicine containing sodium dehydroacetate, which is used for treating helicobacter pylori infection. In order to solve the problems of antibiotic resistance and gastrointestinal tract microecological disorder caused by the existing quadruple therapy, free molecules of the medicine disclosed by the invention under the gastric acid condition have strong lipophilicity, can efficiently penetrate through a gastric mucous layer and bacterial cell membranes, and can cause bacterial energy depletion death by blocking tricarboxylic acid cycle and energy metabolic centers such as succinate dehydrogenase. Animal experiments prove that the curative effect of reducing Hp colonization is equivalent to or even better than that of quadruple therapy. As a non-antibiotic bacteriostatic agent, the product has the advantages that drug resistance is not easy to generate due to multi-target action, normal intestinal flora is not damaged, flora imbalance and secondary infection are effectively avoided, and the safety is obviously improved.

The invention relates to the technical field of biology, and provides an ICU (Intensive Care Unit) multi-drug-resistant bacterium biological membrane removal system based on phage targeted delivery, which comprises a phage screening module for screening a specific phage for targeted lysis of ICU multi-drug-resistant bacteria; the targeted delivery module is used for accurately delivering the bacteriophage or the bacteriophage-drug compound into the biological membrane; the synergistic effect module is used for enhancing the penetrating and cracking effects of the bacteriophage on the biological membrane; the environment adaptation module is used for adjusting the acting environment parameters in the ICU scene; and the effect monitoring module is used for monitoring the biological membrane removal progress and the bacterial residue condition in real time. Drug-resistant bacteria are accurately cleared through specific bacteriophage and targeted delivery, and normal flora is guaranteed; the synergistic module breaks a biological membrane and assists in deep sterilization of bacteriophage; the activity of the bacteriophage is protected through environmental adaptation; and multi-dimensional monitoring and emergency regulation and control are adopted to prevent relapse, so that synergistic interaction and scene adaptability are achieved, the clearing efficiency is greatly improved, and the drug resistance risk is reduced.